Losartan Potassium
Product Images NDC 71335-0698

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl713350698)

Label Image (Lbl713350698)
Losartan Potassium 50mg tablet label from Bryant Ranch Prepack, NDC 71335-0698. The label compares the product to Cozaar 50mg tablet by Citron Pharma LLC. It specifies a package count of 30 tablets, includes storage instructions at room temperature (20°-25°C), a lot number, and a barcode.*
FDA Label Image

Figure 1 (Losartan Fig1)

Figure 1 (Losartan Fig1)
A line graph showing the percentage of patients with primary endpoint over 66 study months comparing Losartan Potassium (solid line) and Atenolol (dotted line). The graph indicates a 13% adjusted risk reduction for Losartan Potassium with a p-value of 0.021, illustrating patient outcome differences over time between the two treatments.*
FDA Label Image

Figure 2 (Losartan Fig2)

Figure 2 (Losartan Fig2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients with stroke from 0 to 8%. The graph includes a note on adjusted risk reduction of 25% with a p-value of 0.001.*
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
A comparative forest plot chart showing primary endpoint event rates and hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol within demographic subgroups. The chart includes data on primary composite outcomes and stroke events, stratified by age, gender, race, isolated systolic hypertension (ISH), diabetes, and cardiovascular disease history among 9193 patients.*
FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
A line chart comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The chart shows Losartan Potassium with a solid line and placebo with a dashed line, indicating a 16.1% risk reduction with Losartan Potassium (p=0.022). The x-axis represents time in months, and the y-axis represents the percentage of patients with events from 0 to 60%.*
FDA Label Image

Chemical Structure (Losartan Str)

Chemical Structure (Losartan Str)
Chemical structure of Losartan Potassium showing its molecular arrangement with key functional groups and the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.